文献速递病毒性肝炎医院感染防控

直接抗病毒药物与器官移植:我们还有什么不能做?

Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
PubMed 文献 · J Infect Dis · 2020-01-01

美国阿片类药物流行导致HCV感染供者增多,直接抗病毒药物使HCV病毒血症器官可移植给伴或不伴HCV感染的受者;本文综述不同实体器官移植的关键研究、近期不良事件报告及伦理监管考量。

要点

  • HCV病毒血症供者器官可移植给伴或不伴HCV感染的受者。
  • 移植后免疫抑制下DAA方案仍可获得高持续病毒学应答率。
  • 策略包括延迟治疗和抢先治疗,需权衡伦理与监管。

核心结论

  • 当前HCV治疗的高效性通过扩大器官移植可及性改善终末期器官衰竭患者生存并降低等待名单死亡率。

研究设计与样本

  • 综述,讨论不同实体器官移植的关键研究、近期不良事件报告及伦理与监管考量。

主要发现

  • 美国阿片类药物流行导致HCV感染供者增多。
  • DAA方案在移植后免疫抑制下仍提供高持续病毒学应答率。
  • HCV病毒血症器官已提供给伴或不伴HCV感染的移植候选者。

关键数值与推荐

  • HCV病毒血症器官移植策略包括延迟治疗和抢先治疗。

临床怎么用

  • 利用HCV病毒血症供者器官扩大移植可及性,需结合延迟或抢先DAA治疗策略。

局限性

  • 本文为综述,未报告原始研究样本量、阈值或疗效数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The opioid epidemic has resulted in an increase in organ donors with hepatitis C virus (HCV) infection in the United States. With the development of direct-acting antiviral regimens that offer high sustained virologic response rates even in the setting of immunosuppression after transplantation, these HCV-viremic organs are now being offered to transplant candidates with or without preexisting HCV infection. Strategies for HCV treatment with HCV-viremic organs have included delayed and preemptive approaches. This review will discuss key studies in the different solid organ transplants, recent reports of adverse events, and ethical and regulatory considerations. The efficacy of current HCV therapies has created this important opportunity to improve survival for patients with end-organ failure through greater access to organ transplantation and decreased waitlist mortality rate.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kappus MR, Wolfe CR, Muir AJ, et al. Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do? J Infect Dis. 2020. PMID: 33245347. doi:10.1093/infdis/jiaa420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。